Gaois

Téarmaí cosúla:

Cóip statach de shonraí a easpórtáiltear ó IATE ó am go chéile atá sa chnuasach seo. Níor cheart glacadh leis gurb ionann i gcónaí an t-eolas a thugtar faoi iontráil anseo agus a bhfuil sa leagan reatha den iontráil ar IATE. Is féidir an leagan reatha sin a cheadú ach cliceáil ar an nasc atá ar thaobh na láimhe deise ag barr gach iontrála. Breis eolais »

3 thoradh

  1. INDUSTRY|chemistry
    cioglaideistrin Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    CDX Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    Cyclodextrin
    de
    CDX | cyclodextrin
    en
    Sainmhíniú "nonreducing cyclic dextrin [ IATE:1087909 ] produced from starch by means of enzymatic conversion" Tagairt "Wikipedia: http://en.wikipedia.org/wiki/Cyclodextrin Amano Enzyme: http://www.amano-enzyme.co.jp/eng/productuse/starch.html [5.9.2011]"
    Nóta "Cyclodextrins (sometimes called cycloamyloses) are a family of compounds made up of sugar molecules bound together in a ring (cyclic oligosaccharides [ IATE:1450479 ]). Cyclodextrins are produced from starch by means of enzymatic conversion. They are used in food, pharmaceutical, and chemical industries, as well as agriculture and environmental engineering. The naming of the cyclodextrin molecule is based on the number and properties of the glucose molecules within the ring portion. Six, Seven, and Eight glucose units that form cyclodextrin molecules are referred to as Alpha, Beta, and Gamma respectively. Wikipedia: http://en.wikipedia.org/wiki/Cyclodextrin Johnberardi.com: http://www.johnberardi.com/articles/supplementation/cyclodextrins.htm [6.9.2011]"
    cyclodextrine | CD
    fr
    Sainmhíniú groupement de forme torique d'au moins 6 unités d'anhydroglucose, unies par des liaisons glucosidiques alpha-1,4 et provenant de l'action d'enzymes produites par certaines bactéries, telles que b. macerans, sur l'amidon ou la fécule Tagairt NF V 00-100:1979
  2. SOCIAL QUESTIONS|health|health policy|organisation of health care|medical device
    diagnóisic chompánaigh Tagairt Faomhadh an téarma seo mar chuid de Thionscadal Lex
    ga
    therapiebegleitendes Diagnostikum
    de
    Sainmhíniú Produkt, das für die sichere und wirksame Verwendung eines dazugehörigen Arzneimittels wesentlich ist, um | a) | Patienten vor und/oder während der Behandlung zu identifizieren, die mit der größten Wahrscheinlichkeit von dem dazugehörigen Arzneimittel profitieren, oder | b) | Patienten vor und/oder während der Behandlung zu identifizieren, bei denen wahrscheinlich ein erhöhtes Risiko von schwerwiegenden unerwünschten Reaktionen infolge einer Behandlung mit dem dazugehörigen Arzneimittel besteht Tagairt "Verordnung (EU) 2017/746 über In-vitro-Diagnostika und zur Aufhebung der Richtlinie 98/79/EG und des Beschlusses 2010/227/EU der Kommission, Art.2 Nr.7; ABl. L_117/2017, S.176 CELEX:32017R0746/DE"
    companion diagnostic | in vitro companion diagnostic device | IVD companion diagnostic device | CDx | companion diagnostics
    en
    Sainmhíniú device which is essential for the safe and effective use of a corresponding medicinal product to:(a)identify, before and/or during treatment, patients who are most likely to benefit from the corresponding medicinal product; or(b)identify, before and/or during treatment, patients likely to be at increased risk of serious adverse reactions as a result of treatment with the corresponding medicinal product. Tagairt "Regulation (EU) 2017/746 on in vitro diagnostic medical devices"
    diagnostic compagnon
    fr
    Sainmhíniú tout dispositif essentiel pour une utilisation sûre et efficace d'un médicament donné visant àa) identifier, avant et/ou pendant le traitement, les patients les plus susceptibles de bénéficier du médicament en question; oub) identifier, avant et/ou pendant le traitement, les patients susceptibles de présenter un risque accru d'effets indésirables graves en réaction au traitement par le médicament en question Tagairt "Règlement (UE) 2017/746 relatif aux dispositifs médicaux de diagnostic in vitro, article 2, point 7)"